Clinical trials: Acute Myelogenous Leukemia (AML)
Leukemia, Lymphoma
Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer
RATIONALE: Giving chemotherapy and total body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00028730
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed/Refractory AML, Relapsed/Refractory ALL
POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
In this Phase I study, we will test the safety of the drug plerixafor (MOBOZIL) at different dose levels, used together with other anti-cancer drugs-cytarabine and etoposide.
- Conditions
- Relapsed/Refractory AML, Relapsed/Refractory ALL, Secondary AML/MDS, Acute Leukemia of Ambiguous Lineage
- Trial name
- NCT01319864
- Testing
- Plerixafor Dose Escalation
- Where
- 9 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- Seattle Children's Hospital
Leukemia
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00372593
- Testing
- asparaginase, cytarabine, daunorubicin hydrochloride
- Where
- 198 sites in United States, Australia and 4 more
- Volunteers
- 1,070 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)
The objective of the phase I part of the trial is the determination of the maximum tolerated dose (MTD) of TCP (Tranylcypromine) in combination with fixed-dose ATRA (all-trans-retinoic acid) and with fixed-dose AraC (Cytarabine)…
- Trial name
- TRANSATRA (NCT02717884)
- Testing
- tranylcypromine, all-trans retinoic acid, cytarabine
- Where
- 6 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Michael Luebbert
Kidney Cancer, Leukemia
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
RATIONALE: Voriconazole may be effective in preventing systemic fungal infections following chemotherapy. PURPOSE: Phase II trial to study the effectiveness of voriconazole in preventing systemic fungal infections in children who…
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00066599
- Testing
- voriconazole
- Where
- 7 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia
This study aims at evaluating the safety and the tolerance of the micro-transplantation in elderly patients with acute myeloid leukemia who are ineligible to conventional allogeneic transplantation.
- Trial name
- MTSA (NCT03439371)
- Testing
- HLA-mismatched micro-transplantation after induction chemotherapy
- Where
- 7 sites in France
- Volunteers
- 12 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
The purpose of phase 1 part in this study was to determine the maximum tolerated dose (MTD) and/or recommended expansion dose (RED) of ASP2215 concomitant with cytarabine/idarubicin as induction chemotherapy based on the status…
- Trial name
- NCT02310321
- Testing
- Gilteritinib, Idarubicin, Cytarabine
- Where
- 55 sites in Japan, South Korea and 1 more
- Volunteers
- 97 people
- Sponsor
- Astellas Pharma Inc
AML - Acute Myeloid Leukemia
Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX
The goal of this observational study is to develop new ways to test new drug combinations to kill tumour cells, in patients with acute myeloid leukemia (AML).
- Trial name
- COSMOS-Avatar (NCT06782971)
- Where
- 4 sites in Australia
- Volunteers
- 25 people
- Sponsor
- Clinical Hub for Interventional Research (CHOIR)
Acute Myeloid Leukemia, Myeloproliferative Neoplasms
Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms
The objective of this study is to describe the prevalence and prognostic impact of the most common genetic abnormalities in patients with Myeloid Neoplasms, including Acute Myeloid Leukemia (AML), Myeloproliferative Neoplasms…
- Conditions
- Acute Myeloid Leukemia, Myeloproliferative Neoplasms, Myelodysplastic Syndromes, Myeloproliferative/Myelodysplastic Neoplasm
- Trial name
- NCT02084563
- Testing
- Induction Chemotherapy, Consolidation Chemotherapy, Autologous Stem Cell Transplantation
- Where
- Brazil
- Volunteers
- 455 people
- Sponsor
- Hospital Israelita Albert Einstein
Acute Myeloid Leukemia
Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)
This study will test an experimental combination of the drugs Mylotarg and 5-azacitidine in the hopes of finding a treatment that may be effective against Acute Myeloid Leukemia that has come back after treatment.
- Trial name
- NCT00766116
- Testing
- 5-Azacitidine, Gemtuzumab ozogamicin
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Acute Myeloid Leukemia
Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia
Ceplene/IL-2 remission maintenance therapy has been shown to significantly prolong Leukemia Free Survival in patients with Acute Myeloid Leukemia (AML) in first complete remission.
- Trial name
- NCT01347996
- Testing
- histamine dihydrochloride and IL-2
- Where
- Sweden
- Volunteers
- 84 people
- Sponsor
- Cytovia, Inc.
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
This phase II trial studies the effect of venetoclax together with busulfan, cladribine, and fludarabine in treating patients with high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing stem cell…
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT04708054
- Testing
- Busulfan, Cladribine, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
AML (Acute Myeloid Leukemia)
Clinical Study of Selinexor-Based Chemotherapy With Minimal or No Cytotoxic Agents in Treatment-Naïve AML Patients Unsuitable for Intensive Therapy: Focusing on Rapid Reduction of Blast Cells
This study aims to evaluate the efficacy and safety of selinexor-based chemotherapy-sparing regimens (including chemotherapy-free or dose-reduced approaches) in optimizing therapeutic strategies for treatment-naïve acute myeloid…
- Trial name
- NCT07236931
- Testing
- the XAB regimen
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Donghua Zhang
Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Persistent Disease
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
This phase II trial studies the side effects and how well Vyxeos works in treating patients with intermediate and high-risk acute myeloid leukemia who have failed an initial cycle of standard cytarabine and daunorubicin…
- Conditions
- Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Persistent Disease, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04049539
- Testing
- Liposome-encapsulated Daunorubicin-Cytarabine
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Acute Myeloid Leukemia
Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and Neutropenia
An open-label, multi-center, Phase Ib study to determine the safety and pharmacokinetics of intravenous and oral APX001 in patients undergoing chemotherapy for Acute Myeloid Leukemia with neutropenia.
- Trial name
- NCT03333005
- Testing
- APX001 with Standard of Care anti-fungal agent
- Where
- 3 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Basilea Pharmaceutica
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Myeloid malignancies which include AML (acute myeloid leukemia) and MDS (myelodysplatic syndrome) are cancers of the bone marrow which lead to bone marrow failure.
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT05184842
- Testing
- Venetoclax, Decitabine
- Where
- 3 sites in United States
- Volunteers
- 91 people
- Sponsor
- Montefiore Medical Center
GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)
Phase I Study of Milatuzumab for Graft Versus Host Disease
This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a standard regimen to prevent Graft vs. Host Disease (GVHD) in patients with hematologic malignancies undergoing stem cell transplant.
- Conditions
- GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome, Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT01663766
- Testing
- milatuzumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Gilead Sciences
Acute Myeloid Leukemia
Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy
Phase II randomized placebo-controlled study to assess the impact on outcome of Eltrombopag administered to elderly patients with Acute Myeloid Leukemia (AML) receiving induction chemotherapy.
- Trial name
- EPAG2015 (NCT03603795)
- Testing
- Eltrombopag
- Where
- 15 sites in France
- Volunteers
- 110 people
- Sponsor
- French Innovative Leukemia Organisation
Leukemia, Myelogenous, Acute
LCI-HEM-SPEC-001: Tissue Collection for Genetic Analysis of Acute Myelogenous Leukemia
The purpose of this study is to obtain high quality specimens for molecular studies for the identification and characterization of genetic mutations involved in the pathogenesis of familial myeloid malignancies.
- Trial name
- NCT01999556
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Leukemia
Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim and sargramostim may increase the number of immune cells found…
- Trial name
- NCT00053131
- Testing
- filgrastim, sargramostim, cytarabine
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute